Editorial Videos

In the final part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses the challenges that pharma faces when marketing direct-to-consumers.

Buzz Health President Joseph Kleiman discusses how TrumpRx is reshaping drug price transparency, highlighting the benefits of early price visibility for consumers alongside the operational challenges of fluctuating costs, consistency and potential.

Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects.

In the second part of his conversation with Pharmaceutical Executive, Sandy Donaldson discusses how pharma marketing teams decide who to target with advertising campaigns.

Jay Bregman, CEO and co-founder of Andel, discusses how pharmaceutical companies and digital health platforms may need to rethink commercialization strategies, shifting away from costly mass-market advertising toward employer-focused distribution models.

Sandy Donaldson discusses how pharma companies are developing precise marketing strategies for the modern world.

Jay Bregman, CEO and co-founder of Andel discusses how FDA’s planned action against non-FDA-approved GLP-1 products could reshape competition in obesity and diabetes care.

Kim Boericke, CEO, Veristat, discusses how Veristat is adapting clinical trials by using data, AI, and operational planning to optimize site selection, manage complex cell and gene therapy logistics, and streamline analytics.

Kim Boericke, CEO, Veristat, touches on how early strategic consulting, data analytics, and automation help optimize trial design, define realistic patient populations, and generate faster insights.

Kim Boericke, CEO, Veristat, notes that advancing women into STEM leadership requires strong advocacy from senior leaders, strategic career planning, and building visibility through cross-functional collaboration and networking.

Yerem Yeghiazarians founder, CEO of Soley Therapeutics, discusses how Soley uses human cells to guide drug discovery, improving translation to patients and transforming how new therapeutics are developed.

Yerem Yeghiazarians founder and CEO of Soley Therapetuics touches on how Soley's approach reverses traditional drug development and reduces failure risks.

Angela Schwab, CEO at Trialynx, continues her conversation with Pharmaceutical Executive, this time detailing her experience with debuting her company at the conference.

Trialynx CEO Angela Schwab discusses where she saw AI succeeding and failing at the healthcare conference.

In the final part of his conversation with Pharmaceutical Executive, Clay Siegall (president and CEO of Immunome) details the next steps for his upcoming medication.

Immunome president and CEO Clay Siegall explains why the weeks following JP Morgan are just as important as the conference itself.

Clay Siegall, president and CEO of Immunome, discusses what he saw investors getting excited for at the annual healthcare conference.

Jeff Liter, CEO of Luminary Therapeutics, discusses the importance of demonstrating clinical evidence at the JP Morgan Healthcare Conference.

Graham Goodrich, CCO, Apnimed, points to 2026 as a pivotal year marked by Apnimed’s planned NDA filing for AD109, the build-out of its commercial infrastructure and access strategy, and preparations for a potential FDA decision in early 2027.

Hayley Burgess SVP, Inovalon, talks about how specialty pharmacists are evolving from dispensers into precision-care partners, using integrated data, automation, and AI to personalize therapy decisions.

Graham Goodrich, CCO, Apnimed, positions AD109 as a long-awaited, patient-acceptable therapy for untreated sleep apnea that delivers meaningful improvements in oxygenation, daily functioning, and peace of mind.

Hayley Burgess SVP, Inovalon, touches on integrated care mentioning to the industry's priority of shared real-time data across payers, providers, and pharmacies, can lead to it becoming reality.

Graham Goodrich, CCO, Apnimed, outlines how advances in diagnostics, growing recognition of sleep apnea’s systemic impact, and emerging oral therapies are driving renewed momentum in sleep medicine as Apnimed advances toward commercialization.

Michael O'Rourke, CEO of Re-Vana Therapeutics, touches on Re-Vana's transition from an academic spinout to a fully established biotech, marked by team expansion, facility growth, and validation of its sustained-delivery platform.

Hayley Burgess SVP, Inovalon, talks about how pharmacies preserve efficiency while strengthening patient care by using technology to unify data, streamline workflows, and proactively monitor high-risk patients across care transitions.

Michael O'Rourke, CEO of Re-Vana Therapeutics, frames Re-Vana's early-stage, platform-led model as credible to public-market investors, pointing to clinical validation of sustained biologic delivery and strong collaboration interest.

Hayley Burgess SVP, Inovalon, talks about rising data fragmentation, access barriers, and adherence risks pushing specialty pharmacies to adopt integrated, end-to-end platforms that consolidate clinical, operational, and patient data.

As part of her continuing conversation with PharmExec, Trialynx CEO Angela Schwab goes into detail the importance of understanding a site’s abilities during the development stage of a trial.